Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31162468 | 0.83 | MEN1 (0.61) | MEN1KMT2APOLBMAPT | |
| SCHEMBL15938387 | 0.80 | TGM2 (0.54) | HDAC2HDAC1TGM2HDAC3ALDH1A1 | |
| SCHEMBL15938644 | 0.80 | TGM2 (0.54) | GSTO1HDAC2HDAC1TGM2HDAC3 | |
| SCHEMBL11336614 | 0.79 | EGFR (0.59) | ALDH1A1KDM4ENPC1RAB9ACYP3A4 | |
| SCHEMBL31162463 | 0.79 | EGFR (0.59) | ALDH1A1KDM4ENPC1RAB9ACYP3A4 | |
| SCHEMBL19575701 | 0.79 | NPC1 (0.52) | MEN1KMT2APOLBFADS1HDAC2 | |
| Hydrochloric Acid SCHEMBL18249511 | 0.79 | TGM2 (0.53) | GSTO1HDAC2HDAC1TGM2HDAC3 | |
| SCHEMBL28043945 | 0.78 | HDAC1 (0.41) | HDAC2HDAC1TGM2HDAC3 | |
| SCHEMBL9210058 | 0.77 | HDAC1 (0.58) | MEN1KMT2APOLBFADS1HDAC2 | |
| SCHEMBL15938598 | 0.76 | TGM2 (0.58) | GSTO1HDAC2HDAC1TGM2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2953457-A2 | ERK INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MEN1 2133/4885KMT2A 2071/4885GSTO1 2454/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | MEN1 1944/4885KMT2A 3528/4885GSTO1 2004/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MEN1 2133/4885KMT2A 2071/4885GSTO1 2454/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MEN1 2133/4885KMT2A 2071/4885GSTO1 2454/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MEN1 2133/4885KMT2A 2071/4885GSTO1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.